OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Genmab A/S Sponsored ADR $GMAB

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 120.8% in the second quarter, Holdings Channel.com reports. The fund owned 158,719 shares of the company’s stock after purchasing an additional 86,842 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Genmab A/S were worth $3,279,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in GMAB. Orbis Allan Gray Ltd raised its holdings in Genmab A/S by 102.8% in the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after purchasing an additional 2,895,179 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after buying an additional 2,084,966 shares during the period. First Trust Advisors LP raised its stake in Genmab A/S by 3.5% in the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after buying an additional 60,504 shares in the last quarter. Brandywine Global Investment Management LLC lifted its holdings in Genmab A/S by 1.6% in the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after buying an additional 27,372 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock valued at $24,634,000 after acquiring an additional 665,893 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on GMAB shares. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. HC Wainwright increased their price objective on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Finally, Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.75.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $31.24 on Thursday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $33.65. The firm’s 50-day moving average is $30.88 and its 200 day moving average is $26.17. The stock has a market cap of $20.07 billion, a price-to-earnings ratio of 13.29, a PEG ratio of 1.61 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. On average, equities analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.